Background and Objectives: the use of neoadjuvant chemotherapy (NAC) in breast cancer induces a pCR in only 30–35% of patients. We can't depend only on clinical and pathological factors to distinguish the patients who have no chance of a pCR or not. Moreover, the NAC scenario is the perfect setting to study possible changes in TIL levels. Tumor-infiltrating lymphocytes (TIL) (CD) 8+ are essential components of tumor-specific cellular adaptive immunity. However, only few studies have addressed the significance of (CD8+) TIL in patients with breast cancer. Patients and Methods: we assessed the stromal and intratumral TIL, CD+8 in pretreatment core biopsy by immuohistochemistry (IHC) in 45 patients with breast cancer received neoadjuvant anthracyclin and docetaxel chemotherapy. CD8 classified into high or low according to the inter quartile range. Tumors with ≥ 50% intratumoral or stromal lymphocytes were designated lymphocyte predominant breast cancer (LPBC). Results: we found statistically significant correlation with high CD8 and DFS and smaller tumor residual (95% CI, 18.6-22.9; P= 0.01) and (p=0.003) respectively. But there was no significant difference regarding pCR or OS between high and low groups. Conclusion: this study confirmed that the CD8 TIL is an important prognostic and predictive factor in breast cancer.